Benzinga · Oct 2, 2026
Stock Market: Will S&P 500 Open Up or Down Today?
S&P 500 to open higher? Polymarket odds reach 70% as Wall Street digests September jobs, 24-year high Treasury yields, and Iran sanctions.
EN
NASDAQ · ENLV
Enlivex Therapeutics Ltd.
Healthcare · Biotechnology
$0.39
Down-$0.04 (-8.37%)
Updated Oct 3, 2026, 6:57 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 23.6M
- P/E ratio
- -1.84
- Dividend yield
- 0.00%
- 52-week range
- $0.41 – $8.12
- Volume
- 631.11K
- Avg. volume
- 3.73M
Price performance · ENLV
ENLV price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
ENLV closed at $0.39 after 20 trading sessions, down 64.79% for the selected period.
- Last close
- $0.39
- Period change
- -64.79%
- Period low
- $0.39
- Period high
- $1.11
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $0.4243 | $0.4299 | $0.38 | $0.3873 | 631.11K |
| Oct 1, 2026 | $0.492 | $0.5018 | $0.4114 | $0.4227 | 756.69K |
| Sep 30, 2026 | $0.481 | $0.58 | $0.4701 | $0.5028 | 972.23K |
| Sep 29, 2026 | $0.52 | $0.53 | $0.47 | $0.4801 | 587.74K |
| Sep 28, 2026 | $0.60 | $0.60 | $0.5027 | $0.514 | 631.02K |
| Sep 25, 2026 | $0.60 | $0.62 | $0.58 | $0.5975 | 317.47K |
| Sep 24, 2026 | $0.6337 | $0.64 | $0.57 | $0.6057 | 381.2K |
| Sep 23, 2026 | $0.633 | $0.6873 | $0.6151 | $0.64 | 594.24K |
| Sep 22, 2026 | $0.69 | $0.709 | $0.5737 | $0.6464 | 1.23M |
| Sep 21, 2026 | $0.84 | $0.85 | $0.6651 | $0.6928 | 671.04K |
| Sep 18, 2026 | $0.7301 | $0.819 | $0.7105 | $0.8066 | 350.08K |
| Sep 17, 2026 | $0.821 | $0.8513 | $0.64 | $0.7272 | 767.72K |
| Sep 16, 2026 | $0.90 | $0.92 | $0.79 | $0.8111 | 410.63K |
| Sep 15, 2026 | $0.88 | $0.92 | $0.87 | $0.8827 | 229.44K |
| Sep 14, 2026 | $0.95 | $1.02 | $0.8637 | $0.8645 | 304.53K |
| Sep 11, 2026 | $1.00 | $1.07 | $0.95 | $0.9595 | 255.98K |
| Sep 10, 2026 | $1.03 | $1.06 | $0.9798 | $0.9807 | 281.54K |
| Sep 9, 2026 | $1.12 | $1.2171 | $1.02 | $1.04 | 287.78K |
| Sep 8, 2026 | $1.10 | $1.19 | $1.06 | $1.11 | 190.5K |
| Sep 4, 2026 | $1.15 | $1.16 | $1.02 | $1.10 | 252.14K |
Latest ENLV news
The latest Smart Investors Daily articles mentioning ENLV.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ENLV research
Overview
Company profile and research snapshot.
Company profile
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 12, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 24, 2025 | D. Boral Capital | Hold | — |
| Oct 29, 2025 | D. Boral Capital | Buy | — |
News briefing
Generated Oct 3, 2026, 3:19 PM
Why Is ENLV Down Today?
Enlivex Therapeutics (ENLV) is experiencing a notable decline of 8.37%, trading down $0.04 as broader market uncertainty weighs on smaller biotech companies. With limited company-specific news in today's headlines, the decline appears largely driven by general market sentiment and sector headwinds affecting smaller-cap therapeutics firms.
Bottom line: ENLV's decline today appears driven primarily by macro market uncertainty rather than company-specific headwinds, presenting both a warning sign about sector sentiment and a potential opportunity for value-oriented investors. Key catalysts to monitor include clinical trial data, regulatory announcements, and any strategic partnerships that could validate the company's immunotherapy platform and justify a re-rating higher.
Yahoo · Sep 1, 2026
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Benzinga · Aug 3, 2026
HC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $80
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex (NASDAQ:ENLV) with a Buy and raises the price target from $20 to $80.
Benzinga · Jul 30, 2026
Enlivex Announces Trading Volume On Rain Protocol Reaches $860M
Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today provided an update on the Rain protocol trading metrics. Trading
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
